Alector Inc (NASDAQ:ALEC) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue ...

Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...

Alector (NASDAQ:ALEC) is scheduled to announce Q4 earnings results on Wednesday, February 26th, after market close. The consensus EPS Estimate is -$0.54 (-10.2% Y/Y) and the consensus Revenue Estimate ...

在充满挑战的市场环境下，Alector Inc (ALEC)股价触及新的52周低点，跌至1.59美元。这一显著下跌反映了该生物科技公司的整体趋势，过去一年股价已下跌了75.15%。根据 InvestingPro ...

Alector (NASDAQ:ALEC – Get Free Report) is anticipated to post its quarterly earnings results after the market closes on ...

北京时间2025年01月31日02时20分，Alector, Inc.（ALEC.us）股票出现异动，股价急速拉升5.18%。截至发稿，该股报1.73美元/股，成交量 ...

北京时间2025年01月29日02时36分，Alector, Inc.（ALEC.us）股票出现异动，股价大幅下跌5.17%。截至发稿，该股报1.65美元/股，成交量 ...

11月26日｜美国生物制药公司Alector(ALEC.US)盘前跌超33.5%，报2.63美元。消息面上，Alector表示，该公司的实验性药物在一项中期试验中没有达到减缓阿尔 ...

In a challenging market environment, Alector Inc (NASDAQ:ALEC) stock has touched a new 52-week low, with shares plummeting to $1.59. This significant downturn reflects a broader trend for the ...

Alector, Inc., a late-stage clinical biotechnology company, is advancing its preclinical and research pipeline focused on genetically-validated therapies for neurodegenerative diseases.

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the ...